FDA Grants Full Approval to Blinatumomab for Acute Lymphoblastic Leukemia

News   Jul 27, 2017 | Original story from NIH

 
FDA Grants Full Approval to Blinatumomab for Acute Lymphoblastic Leukemia

Credit: Christaras A, CC BY 2.5

 
 
 

RELATED ARTICLES

BIA Separations appoints Pete Gagnon as Chief Scientific Officer

News

Appointment will drive new product and applications development.

READ MORE

PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug Development

News

Will shorten timelines, reduce costs and simplify contracting process in pediatric programs.

READ MORE

Glythera Appoints Chief Scientific Officer and Strengthens SAB

News

Dr Robert Lutz appointed as CSO to support development of next-generation PermaLink® Antibody Drug Conjugates. Dr Jon Roffey appointed to Scientific Advisory Board.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE